Some policy reforms can help incentivize more use of value-based contracts, but overall an area that needs more work is value-based contracts with pharmaceutical companies, said Steven Peskin, MD, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Some policy reforms can help incentivize more use of value-based contracts, but overall an area that needs more work is value-based contracts with pharmaceutical companies, said Steven Peskin, MD, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Transcript
What policy reforms are needed in order to successfully incentivize the use of value-based contracts?
There are policy reforms related to that recognition that self-referral and the so-called Stark amendment may not be in the best interest of or it has a negative impact on value-based arrangements. So, that that would certainly be one.
I would say another would be that with commercial payers oftentimes, at least to some extent taking some license or following or acknowledging the important role of the Centers for Medicare and Medicaid Services and Center for Medicare and Medicaid Innovation. So, the OCM [Oncology Care Model] as well intentioned as it was didn't end up working very well. And it just doesn't apply to cancer care other areas, as well. So that kind of thought leadership and framing at the federal level that allows some of the private payers, commercial payers like ours to work within a particular policy framework. So, there's a couple of things that come to mind,
How have value-based contracts with pharmaceutical companies progressed?
The number of value-based contracts that exist between pharmaceutical/life sciences companies, biopharmaceuticals, cell therapy, gene therapy, is really few and far between. And it really is an area that needs to evolve. It’s something that is sort of a societal expectation, the way in which we as a nation approach health care and percentage of the gross domestic product. So, it’s definitely a work in progress and it needs a lot of work.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More